четверг, 19 мая 2016 г.

Valeant Weighs Sale of Skin, Cancer Drugs to Reduce Debt

Valeant Weighs Sale of Skin, Cancer Drugs to Reduce Debt


Valeant Pharmaceuticals International Inc. is exploring the sale of some of its smaller cosmetic and pharmaceutical assets, according to people familiar with the matter, as the Canadian drugmaker scrambles to raise cash and reduce debt. The company is considering the disposal of Obagi Medical Products Inc., a dermatology company it acquired in 2013, as well as Provenge, a treatment for advanced prostate cancer that was purchased last year, said the people, who asked not to be identified because the matter is private.



from Biotech News